alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 60, Number 83 (Monday, May 1, 1995)]
[Notices]
[Page 21188]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10569]



-----------------------------------------------------------------------

DEPARTMENT OF ENERGY
[Docket Nos. RP95-197-000 and RP95-197-001]


Transcontinental Gas Pipe Line Corporation; Notice of Technical 
Conference

April 25, 1995.
    Pursuant to the Commission's order issued on March 31, 1995,\1\ a 
technical conference will be convened to discuss Transcontinental Gas 
Pipe Line Corporation's (Transco) proposed tariff revisions, Transco's 
proposed new services under Rate Schedule ICTS and GMS, as well as any 
other issues concerning Transco's terms and conditions, or system 
operations. The conference will be held on Wednesday, May 17, 1995, at 
10:00 a.m. in a room to be designated at the offices of the Federal 
Energy Regulatory Commission, 810 First Street, N.E., Washington, D.C. 
20426.

    \1\Transcontinental Gas Pipe Line Corporation, 70 FERC 61,384 
(1995).
---------------------------------------------------------------------------

    All interested persons and staff are permitted to attend.
Lois D. Cashell,
Secretary.
[FR Doc. 95-10569 Filed 4-28-95; 8:45 am]
BILLING CODE 6717-01-M
Ronnie JOHNSON, petitioner, v. FLORIDA.

No. 12-8038.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the District Court of Appeal of Florida, Second District, denied.
<TABLE> <S> <C>


<ARTICLE>                                            9
<RESTATED>
<MULTIPLIER>                  1,000

       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                       MAR-31-1998
<PERIOD-START>                          JAN-01-1998
<PERIOD-END>                            MAR-31-1998
<CASH>                                       21,897  
<INT-BEARING-DEPOSITS>                        2,405  
<FED-FUNDS-SOLD>                             24,500  
<TRADING-ASSETS>                                  0  
<INVESTMENTS-HELD-FOR-SALE>                 321,909  
<INVESTMENTS-CARRYING>                      106,291  
<INVESTMENTS-MARKET>                        109,628  
<LOANS>                                     646,665  
<ALLOWANCE>                                   8,535  
<TOTAL-ASSETS>                            1,160,623  
<DEPOSITS>                                  957,883  
<SHORT-TERM>                                      0  
<LIABILITIES-OTHER>                          12,546  
<LONG-TERM>                                  83,653  
<PREFERRED-MANDATORY>                             0  
<PREFERRED>                                       0  
<COMMON>                                     71,173  
<OTHER-SE>                                   15,231  
<TOTAL-LIABILITIES-AND-EQUITY>            1,160,523  
<INTEREST-LOAN>                              14,053  
<INTEREST-INVEST>                             7,091  
<INTEREST-OTHER>                                626  
<INTEREST-TOTAL>                             21,770  
<INTEREST-DEPOSIT>                            9,547  
<INTEREST-EXPENSE>                           11,519  
<INTEREST-INCOME-NET>                        10,251  
<LOAN-LOSSES>                                   310  
<SECURITIES-GAINS>                              373  
<EXPENSE-OTHER>                               6,461  
<INCOME-PRETAX>                               4,783  
<INCOME-PRE-EXTRAORDINARY>                    4,783  
<EXTRAORDINARY>                                   0  
<CHANGES>                                         0  
<NET-INCOME>                                  3,285  
<EPS-PRIMARY>                                  0.21  
<EPS-DILUTED>                                  0.19  
<YIELD-ACTUAL>                                    0  
<LOANS-NON>                                   6,794  
<LOANS-PAST>                                    250  
<LOANS-TROUBLED>                                739  
<LOANS-PROBLEM>                                 100  
<ALLOWANCE-OPEN>                              8,260  
<CHARGE-OFFS>                                    48  
<RECOVERIES>                                     23  
<ALLOWANCE-CLOSE>                             8,535  
<ALLOWANCE-DOMESTIC>                          8,535  
<ALLOWANCE-FOREIGN>                               0
<ALLOWANCE-UNALLOCATED>                           0  
        
                                       

</TABLE>
<PAGE>

                                                                      Exhibit 11

                        CENTOCOR, INC. AND SUBSIDIARIES
                COMPUTATION OF EARNINGS (LOSS) PER COMMON SHARE
                                  (unaudited)
                     (in thousands, except per share data)


Computation of Earnings (Loss) Per Common Share

<TABLE> 
<CAPTION> 
                                                         Three months ended        Six months ended
                                                               June 30,                 June 30,
                                                         1997         1996         1997        1996
                                                        ------       ------       ------      ------
<S>                                                     <C>          <C>          <C>         <C> 
PRIMARY:

    Weighted average shares outstanding                 69,688       67,645        69,603     63,901
    Net effect of dilutive stock option and warrants
      based on the treasury stock method using
      average market price                               1,909            -         2,026          -
                                                      ---------    ---------     ---------  ---------

    Totals                                              71,597       67,645        71,629     63,901
                                                      =========    =========     =========  =========

    Net income (loss)                                  $   720     ($ 4,323)      $ 3,991   ($14,021)
                                                      =========    =========     =========  =========

    Per share amount                                   $  0.01     ($  0.06)      $  0.06   ($  0.22)
                                                      =========    =========     =========  =========

  FULLY DILUTED:

    Weighted average shares outstanding                 69,688       67,645        69,603     63,901
    Net effect of dilutive stock option and warrants
      based on the treasury stock method using
      average market price which is greater than
      quarter-end market price                           1,909            -         2,026          -
                                                      ---------    ---------     ---------  ---------

    Totals                                              71,597       67,645        71,629     63,901
                                                      =========    =========     =========  =========

    Net income (loss)                                  $   720     ($ 4,323)      $ 3,991   ($14,021)
                                                      =========    =========     =========  =========

    Per share amount                                   $  0.01     ($  0.06)      $  0.06   ($  0.22)
                                                      =========    =========     =========  =========
</TABLE> 

Note:  Common stock equivalents which would have an antidilutive effect on the
       calculations of per share data are not included in the above analysis.
Exhibit 31.01
                                 CERTIFICATION

I, Michael Pacult, chief executive officer and chief financial officer of
TriView Capital Management, Inc., the managing member of TriView Global Fund,
LLC (the "Fund" or the "Registrant"), does hereby certify that:

1.   I have reviewed this quarterly report on Form 10-Q of the Fund;

2.   Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;

4.   The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

  (a)   Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being
prepared;

  (b)   Evaluated the effectiveness of the registrant's disclosure controls
and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and

  (c)   Disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of
an annual report) that has materially affected, or is reasonable likely to
materially affect, the registrant's internal control over financial
reporting; and

5.   The registrant's other certifying officer and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to
the registrant's auditors and the audit committee of the registrant's board
of directors (or persons performing the equivalent functions):

  (a)   All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

  (b)   Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control
over financial reporting.



By: /s/ Michael Pacult
Michael Pacult



Date: November 20, 2006
[Federal Register Volume 60, Number 11 (Wednesday, January 18, 1995)]
[Notices]
[Page 3647]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-1125]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF THE INTERIOR

Bureau of Reclamation


Josephine County Water Management Improvement, Fish Passage 
Improvements, Savage Rapids Dam, Oregon

AGENCY: Bureau of Reclamation, Interior.

ACTION: Notice of public hearing on planning report/draft environmental 
statement (PR/DES); INT-DES-94-51.

-----------------------------------------------------------------------

SUMMARY: Pursuant to the National Environmental Policy Act of 1969, as 
amended, the Bureau of Reclamation has prepared a planning report/draft 
environmental statement (PR/DES) on a proposed project to improve fish 
passage at Savage Rapids Dam located on the Rogue River in southwest 
Oregon near the city of Grants Pass. A public hearing will be held to 
receive comments from interested organizations and individuals on the 
environmental impacts of the project.

DATES: The public hearing is scheduled from 1:30-10:00 p.m. with a 
break from 5:00-6:30 p.m. on February 16, 1995 in Grants Pass, Oregon.

ADDRESSES: The hearing will be held at: Josephine County Fairgrounds, 
Redwood Highway, 1451 Fairgrounds Road, Colonial Bank Floral Exhibit 
Building, Grants Pass, Oregon.
    Written comments and requests to testify are to be submitted to: 
Regional Director, Bureau of Reclamation, Pacific Northwest Region, 
Attention: PN-6309, 1150 North Curtis Road, Boise, Idaho 83706-1234, 
Telephone (208) 378-5087.

FOR FURTHER INFORMATION CONTACT:
Bureau of Reclamation, Pacific Northwest Region, Attention: PN-6309.

SUPPLEMENTARY INFORMATION: Organizations and individuals wishing to 
present statements at the hearing should contact the Bureau of 
Reclamation, Pacific Northwest Region, to announce their intention to 
participate. Requests for scheduled presentations will be accepted 
through February 10, 1995.
    Oral comments at the hearing will be limited to 5 minutes. The 
hearing officer may allow any speaker to provide additional oral 
comments after all persons wishing to comment have been heard. Whenever 
possible, speakers will be scheduled according to the time preference 
(afternoon or evening) mentioned in their letter or telephone requests. 
Speakers not present when called will lose their privilege in the 
scheduled order and will be recalled at the end of the scheduled 
speakers.
    Written comments from those unable to attend or those wishing to 
supplement their oral presentations at the hearing should be received 
by Reclamation's Pacific Northwest Regional Office at the above address 
by February 27, 1995, for inclusion in the hearing record.

    Dated: January 11, 1995.
John W. Keys, III,
Regional Director, Pacific Northwest Region.
[FR Doc. 95-1125 Filed 1-17-95; 8:45 am]
BILLING CODE 4310-94-M
Juan T. JONES, petitioner, v. Rick THALER, Director, Texas Department of Criminal Justice, Correctional Institutions Division.

No. 12-9634.

Supreme Court of the United States

June 10, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
LA SANTÉ 

CARDIAQUE

Vous pensez peut-être que les maladies 

du cœur ne touchent que les hommes. 

Ce n’est pas vrai. Les maladies du 

cœur sont la principale cause de décès 

chez les femmes.

La FDA a des conseils pour vous 

aider à prendre de bonnes décisions 

concernant votre cœur.

Bureau de la santé des femmes de la FDA

www.fda.gov/womenshearthealth 

Obtenez les faits sur 

l’aspirine.

L’utilisation quotidienne d’aspirine pour prévenir 

les crises cardiaques ou un accident vasculaire 

cérébral ne convient pas à tout le monde.

• D emandez à votre professionnel de la santé si vous 

devez utiliser de l’aspirine.

• Si l ’aspirine vous convient, découvrez :

-Combien vous devriez en prendre.

-À quelle fréquence vous devriez le prendre.

-P endant combien de temps vous devriez prendre 

de l’aspirine. Certains produits combinent 

l’aspirine avec d’autres ingrédients et ne sont pas 

destinés à une utilisation à long terme. 

• I nformez votre professionnel de la santé de tous 

les médicaments et suppléments que vous prenez. 

Votre risque de saignement peut être plus élevé si 

vous utilisez de l’aspirine tout en prenant de certains 

médicaments, vitamines ou herbes.

Connaissez les signes 

d’une crise cardiaque.

Les signes d’une crise cardiaque peuvent 

être différents pour les femmes que pour les 

hommes.

• Une f orte douleur dans la poitrine ou le dos entre les 

omoplates

• Une douleur aiguë dans le haut du corps

• Essoufflement

• É clater dans une sueur froide

• F atigue inhabituelle ou inexpliquée

• S e sentir étourdie ou avoir la tête qui tourne

• A voir la nausée
LA SANTÉ 

CARDIAQUE

Cette fiche d’information a été conçue par le Bureau de la santé des femmes de la FDA. 

Pour en savoir plus sur la santé cardiaque des femmes, accédez au site internet de la FDA:

www.fda.gov/womenshearthealth

Gérez votre état 

de santé.

Des problèmes de santé courants tels que 

l’hypertension artérielle, le diabète et un 

taux de cholestérol élevé peuvent augmenter votre risque de maladie du cœur.

• Prenez vos médicaments comme indiqué. 

N’arrêtez pas de prendre vos médicaments 

à moins que votre médecin ne vous dise que 

vous pouvez le faire.

• Si vous avez du diabète, vérifiez votre glycémie. 

• Faites tester votre tension artérielle et votre 

taux de cholestérol. 

• Demandez à votre médecin comment vous 

devez gérer vos problèmes de santé pendant la 

grossesse.

• Certaines femmes ont besoin d’un appareil 

pour aider leur cœur à fonctionner. Discutez 

avec votre médecin de l’appareil qui convient le 

mieux à votre problème cardiaque.

2020

Mangez des aliments 

sains pour le cœur.

Les informations nutritionnelles sur les étiquettes des aliments peuvent vous aider à 

faire des choix alimentaires sains.

• Choisissez des aliments « faibles en sel » ou « 

faibles en sodium ».

• Limit ez les aliments contenant des « acides gras 

insaturés » ou « gras trans ». Trop de gras trans 

peut provoquer des crises cardiaques.

• R éduisez votre consommation de sucre. Le sucre 

est également étiqueté comme « glucose », « 

fructose », « saccharose » et « sirop de maïs. 

LA SANTÉ CARDIAQUE (FRENCH)
Exhibit 14

- Filed Under Seal -

Case 5:17-cv-00551-LHK Document 285-15 Filed 10/18/18 Page 1 of 1
### I N THE UNI TED STATES COURT OF APPEALS FOR THE FI F TH CI RCUI T

No. 13-60194 Summary Calendar

TERRY W. STEWART, Petitioner-Appellant

v. MARCUS MARTIN, Warden, Respondent-Appellee

Appeal from the United States District Court f or the Southern District of Mississippi U SDC No. 5:13-CV-4

Before BENAVIDES, CLEMENT, and OWEN, Circuit Judges. PER CURIAM: * T e rry W

. S t e w a rt , f

e d e r a l p ri s oner # 17057-075, appeals the district court ’ s dismissal of his 28 U.S.C. § 2241 petition challenging his 2001 conviction in the Western District of North Carolina o n multiple counts of conspiracy, mail fraud, wire fraud, and money laundering. In his petition, Stewart alleged that the trial court violated h i s S i x t h Amendment rights when i t quashed his subpoena of codefendant Phillip Vaughan and d enied his request to introduc e V a u ghan’s hearsay statements a t t r ial. According to S tewart, his c laims were p roperly U n i t e d S t a te s C o u rt o f A p p e al s

F i f t h C i rc u i t 

### F I L E D October 8, 2013 Ly l e W . Cay ce Clerk

* Purs uant to 5 T H C I R

. R

. 47. 5, the court has d eterm ined that this op inion should not be p ublis hed and is not p reced ent excep t und er the lim ited circum s tances s et forth in 5 T H C I R

. R. 47. 5. 4. Case: 13-60194 Document: 00512400375 Page: 1 Date Filed: 10/08/2013No. 13-60194

brought u nder § 2241 via the savings clause o f 28 U.S.C. § 2 255 because he was asserting a claim of actual innocence. A federal prisoner can proceed via § 2241 only if h e shows that relief under § 2255 is inadequate or ineffective, which in turn requires him to demonstrate under the savings clause that his claim (i) is based o n a retroactively applicable Supreme Court decision which established that he may have been convicted of

a nonexistent offense and (ii) was foreclosed by c i rcuit law at t he time when the claim should have been raised in his t rial, d irect appeal, or first § 2255 motion. Reyes-Requena v. United States , 243 F.3d 893, 904 (5th C ir. 2001). Stewart has failed to make t he requisite showing. He has also not s h own that his claim of actual innocence provides an exception to t he requirement that a p e titioner first satisfy t h e savings clause of § 2255 in order to challeng e h i s c o n v i ction and sentence in a § 2241 petition. Therefore, t h e district court did not err in concluding that Stewart could not bring his claims in a § 22 4 1 p e tition. See Jeffers v. Chandler , 253 F.3d 827, 830-31 (5th Cir. 2001). The district court also did not err in concluding that, to the extent Stewart’s petition could be construed

as a § 2255 m otion, the court l acked jurisdiction. See § 2255(a); Solsona v. Warden, F.C.I. , 8 21 F.2d 1129, 11 3 2 (5th Cir. 1987). Accordingly, the district court’s judgment is AFFIRMED.

2 Case: 13-60194 Document: 00512400375 Page: 2 Date Filed: 10/08/2013
MOSCOW , IDAHO , APRIL 10, 2024, AT 8:50 A.M.

IN THE SUPREME COURT OF THE STATE OF IDAHO

STATE OF IDAHO,

Plaintiff

- Respondent,

v.

DESIREE ELAINE KARST,

Defendant

- Appellant. ) ) ) ) ) ) ) ) ) ) Docket No. 50130

- 2022

Appeal from the District Court of the First Judicial District of the State of Idaho, Kootenai County. Barry McHugh, District Judge.

Erik R. Lehtinen , State Appellate Public Defender, Boise, for Appellant.

Raúl R. Labrador, Idaho Attorney General, Boise, for Respondent.

Desiree Elaine Karst appeals the district court’s denial of h er m otion to r eimburse various

fees she paid as a result of her now

- invalidated conviction.

Karst entered a conditional guilty plea reserving the right to appeal for possession of methamphetamine

, marijuana, and drug paraphernalia . On appeal, Karst argued that the district court erred in denying Karst’s motion to suppress drug and paraphernalia evidence. The Idaho Supreme Court reversed the district court’s denial of Karst's motion to suppress. On remand, Karst’s charges were dismi ssed.

Karst filed a m otion to r eimburse various fees and charges she was ordered to pay as a

result of her now

- invalidated conviction. The district court denied the motion for lack of jurisdiction. On appeal, Karst argues that the district court has personal and subject matter jurisdiction to consider her motion and any caselaw to the contrary should be overruled

. Additionally, Karst argues that o rdering r eimbursement remedies a continuing violation of her due process rights.
**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporationby reference in Registration Statement of Discover Bank and Discover Card Execution Note Trust (Registration Numbers 333-141703, 333-141703-01, 333-141703-02, 333-167413, 333-167413-01 and 333-167413-02) on Form S-3 of our Reports of IndependentRegistered Public Accounting Firm dated February 21, 2012 relating to Management’s Assertions on Compliance with Regulation AB Criteria, appearing in the Annual Report on Form 10-K of Discover Card Execution Note Trust for the year endedNovember 30, 2011, and to the reference to us under the heading “Experts” in the Prospectus, which is part of this Registration Statement. 

/s/ Deloitte & Touche LLP 

Chicago, Illinois 

February 21, 2012
Exhibit
32





CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002





The
undersigned have executed this certification in connection with the filing with
the Securities and Exchange Commission of the Company’s Annual Report on Form
10-K for the period ending June 30, 2008.  The undersigned hereby
certify that to our knowledge:





(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.








Dated:   October
14,
2008                          /s/Fred Zolla


Fred
Zolla


President
and Chief Executive Officer


(Principal
Executive Officer)








Dated:   October
14,
2008                         
/s/Craig Stout


Craig
Stout


Chief
Operating Officer and Interim Chief Financial Officer
ST. MARY'S MEDICAL CENTER, INC., dba St. Mary's Medical Center, petitioner, v. R.K.

No. 12-1007.

Supreme Court of the United States

April 1, 2013.

Petition for writ of certiorari to the Supreme Court of Appeals of West Virginia denied.
Anthony BARTON, petitioner, v. FLORIDA.

No. 12-7364.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the District Court of Appeal of Florida, Second District, denied.